Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a rise in its stock price by 3.38 in relation to its previous close of 1.43. However, the company has experienced a 8.71% gain in its stock price over the last five trading sessions. zacks.com reported 2025-04-08 that The FDA’s fast track designations will facilitate rapid development and expedited review of ALLO’s autoimmune disease candidate.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
Company’s 36-month beta value is 0.61.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 5 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ALLO is 139.53M, and currently, short sellers hold a 24.91% ratio of that floaft. The average trading volume of ALLO on April 15, 2025 was 5.42M shares.
ALLO’s Market Performance
ALLO’s stock has seen a 8.71% increase for the week, with a -20.09% drop in the past month and a -23.00% fall in the past quarter. The volatility ratio for the week is 12.71%, and the volatility levels for the past 30 days are at 9.80% for Allogene Therapeutics Inc The simple moving average for the past 20 days is -1.20% for ALLO’s stock, with a -35.64% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Citizens JMP repeating the rating for ALLO by listing it as a “Mkt Outperform.” The predicted price for ALLO in the upcoming period, according to Citizens JMP is $5 based on the research report published on March 14, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11, previously predicting the price at $13. The rating they have provided for ALLO stocks is “Outperform” according to the report published on August 08th, 2024.
Piper Sandler gave a rating of “Overweight” to ALLO, setting the target price at $11 in the report published on May 31st of the previous year.
ALLO Trading at -15.35% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.90% of loss for the given period.
Volatility was left at 9.80%, however, over the last 30 days, the volatility rate increased by 12.71%, as shares sank -12.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.08% lower at present.
During the last 5 trading sessions, ALLO rose by +9.19%, which changed the moving average for the period of 200-days by -39.14% in comparison to the 20-day moving average, which settled at $1.4967. In addition, Allogene Therapeutics Inc saw -30.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Chang David D, who sale 46,668 shares at the price of $1.96 back on Mar 14 ’25. After this action, Chang David D now owns 5,276,569 shares of Allogene Therapeutics Inc, valued at $91,469 using the latest closing price.
Beneski Benjamin Machinas, the SVP, Chief Technical Officer of Allogene Therapeutics Inc, sale 5,488 shares at $1.98 during a trade that took place back on Mar 14 ’25, which means that Beneski Benjamin Machinas is holding 218,507 shares at $10,839 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -12191.36 for the present operating margin
- -326.23 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -11708.64. The total capital return value is set at -0.52. Equity return is now at value -55.13, with -43.24 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.21. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -1481.82.
Currently, EBITDA for the company is -243.33 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 15174.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.54.
Conclusion
In a nutshell, Allogene Therapeutics Inc (ALLO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
